📊 NUVL Key Takeaways
Is Nuvalent, Inc. (NUVL) a Good Investment?
Nuvalent is a pre-profitable pharmaceutical company with a strong balance sheet but severe operational challenges. With $25.3M in quarterly revenue against $119.4M operating losses and $92.4M cash burn per quarter, the company faces approximately 1.7 quarters of runway despite $1.3B in total assets. While the absence of debt is favorable, the severity of losses and limited cash runway require immediate revenue acceleration or cost restructuring to avoid dilutive financing.
Nuvalent exhibits pre-commercial fundamentals: minimal revenue and extremely negative operating and free cash flow driven by heavy R&D spend. While the balance sheet shows strong liquidity and no debt, current cash appears insufficient relative to the burn rate, implying likely future financing needs. Without visibility to durable revenue or profitability, fundamentals skew unfavorable despite runway strength.
Why Buy Nuvalent, Inc. Stock? NUVL Key Strengths
- Zero debt with 0.00x debt-to-equity ratio and only $156.8M in total liabilities
- Strong balance sheet with $1.3B in total assets and $1.2B in stockholders equity
- Exceptional liquidity with 16.14x current and quick ratios; $159.7M cash available
- Very strong liquidity (15.3x current ratio)
- No long-term debt; zero leverage risk
- Large equity base and asset position supporting near-term runway
NUVL Stock Risks: Nuvalent, Inc. Investment Risks
- Severe cash burn of $92.4M per quarter with estimated runway of only 1.7 quarters at current burn rate
- Operating and net margins of -472% and -431.9% respectively, indicating fundamentally unprofitable operations
- Revenue of $25.3M insufficient to cover $119.4M operating losses, requiring either major revenue growth or cost reduction
- Substantial clinical and regulatory execution risk typical of pharmaceutical development stage companies
- High probability of dilutive equity financing requirement to extend operations
- Sustained heavy operating losses with extreme negative margins
- High cash burn relative to cash on hand; potential dilution from future capital raises
- Execution risk on R&D, clinical/regulatory milestones, and commercialization timing
Key Metrics to Watch
- Quarterly operating cash burn rate and estimated cash runway
- Revenue growth trajectory and market adoption of commercial products
- Operating expense levels and cost reduction initiatives
- Clinical pipeline progress and regulatory milestones
- Capital raising activities and potential shareholder dilution
- Quarterly operating cash flow (burn rate) and runway
- Cash & equivalents (and short-term investments) relative to 12–24 month needs
Nuvalent, Inc. (NUVL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 16.14x current ratio provides a solid financial cushion.
NUVL Profit Margin, ROE & Profitability Analysis
NUVL vs Healthcare Sector: How Nuvalent, Inc. Compares
How Nuvalent, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nuvalent, Inc. Stock Overvalued? NUVL Valuation Analysis 2026
Based on fundamental analysis, Nuvalent, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nuvalent, Inc. Balance Sheet: NUVL Debt, Cash & Liquidity
NUVL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nuvalent, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.17 indicates the company is currently unprofitable.
NUVL Revenue Growth, EPS Growth & YoY Performance
Nuvalent, Inc. Dividends, Buybacks & Capital Allocation
NUVL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nuvalent, Inc. (CIK: 0001861560)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUVL
What is the AI rating for NUVL?
Nuvalent, Inc. (NUVL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 73% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUVL's key strengths?
Claude: Zero debt with 0.00x debt-to-equity ratio and only $156.8M in total liabilities. Strong balance sheet with $1.3B in total assets and $1.2B in stockholders equity. ChatGPT: Very strong liquidity (15.3x current ratio). No long-term debt; zero leverage risk.
What are the risks of investing in NUVL?
Claude: Severe cash burn of $92.4M per quarter with estimated runway of only 1.7 quarters at current burn rate. Operating and net margins of -472% and -431.9% respectively, indicating fundamentally unprofitable operations. ChatGPT: Sustained heavy operating losses with extreme negative margins. High cash burn relative to cash on hand; potential dilution from future capital raises.
What is NUVL's revenue and growth?
Nuvalent, Inc. reported revenue of $25.3M.
Does NUVL pay dividends?
Nuvalent, Inc. does not currently pay dividends.
Where can I find NUVL SEC filings?
Official SEC filings for Nuvalent, Inc. (CIK: 0001861560) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUVL's EPS?
Nuvalent, Inc. has a diluted EPS of $-1.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUVL a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Nuvalent, Inc. has a SELL rating with 73% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NUVL stock overvalued or undervalued?
Valuation metrics for NUVL: ROE of -9.3% (sector avg: 15%), net margin of -431.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NUVL stock in 2026?
Our dual AI analysis gives Nuvalent, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NUVL's free cash flow?
Nuvalent, Inc.'s operating cash flow is $-92.4M, with capital expenditures of N/A. FCF margin is -365.2%.
How does NUVL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -431.9% (avg: 12%), ROE -9.3% (avg: 15%), current ratio 16.14 (avg: 2).